Åkerberg D, Ansari D, Andersson R. Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol 2016; 22(28): 6424-6433 [PMID: 27605878 DOI: 10.3748/wjg.v22.i28.6424]
Corresponding Author of This Article
Roland Andersson, MD, PhD, Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, SE-221 85 Lund, Sweden. roland.andersson@med.lu.se
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 28, 2016; 22(28): 6424-6433 Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6424
Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas
Daniel Åkerberg, Daniel Ansari, Roland Andersson
Daniel Åkerberg, Daniel Ansari, Roland Andersson, Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, SE-221 85 Lund, Sweden
Author contributions: Åkerberg D and Ansari D conducted the literature search and drafted the manuscript; Andersson R conceived the study; all authors were involved in manuscript writing and read and approved the final manuscript.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Roland Andersson, MD, PhD, Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, SE-221 85 Lund, Sweden. roland.andersson@med.lu.se
Telephone: +46-46-172359
Received: March 24, 2016 Peer-review started: March 25, 2016 First decision: May 12, 2016 Revised: May 24, 2016 Accepted: June 15, 2016 Article in press: June 15, 2016 Published online: July 28, 2016 Processing time: 119 Days and 19.3 Hours
Abstract
Pancreatic ductal adenocarcinoma carries a poor prognosis with annual deaths almost matching the reported incidence rates. Surgical resection offers the only potential cure. Yet, even among patients that undergo tumor resection, recurrence rates are high and long-term survival is scarce. Various tumor-related factors have been identified as predictors of survival after potentially curative resection. These factors include tumor size, lymph node disease, tumor grade, vascular invasion, perineural invasion and surgical resection margin. This article will re-evaluate the importance of these factors based on recent publications on the topic, with potential implications for treatment and outcome in patients with pancreatic cancer.
Core tip: Many studies have investigated morphological indicators of survival in patients with resectable pancreatic cancer. This article scrutinizes the recent literature related to these classical prognostic factors and examines whether these factors still are able to influence patients’ outcomes in the era of multimodal treatment.
